Purpose Chemoimmunotherapy has been the standard of care for chronic lymphocytic
leukemia (CLL). However, the introduction of B-cell receptor (BCR) kinase inhibitors such as …

Hodgkin Lymphoma HL can be cured in the large majority of younger patients, but prognosis
for older patients, especially those with advanced-stage disease, has not improved …

Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly
heterogeneous and no specific markers to predict sensitivity to this drug have been reported …

Purpose To examine the outcomes associated with granulocyte colony stimulating factors (G-
CSFs) administered as primary versus secondary prophylaxis in setting of bendamustine …

Chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world,
is primarily a disease of the elderly, with most patients≥ 65 years of age and having at least …

Актуальность и цели. Новые схемы противоопухолевой терапии хронического
лимфолейкоза (ХЛЛ) привели к улучшению показателей выживаемости относительно …

Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy characterized by
the expansion and progressive accumulation of mature autoreactive B lymphocytes. The …

Bendamustine is an established treatment option in chronic lymphocytic leukemia (CLL) and
frequently used in Austria and Italy. Therefore, we analyzed 100 unselected, consecutive …

Side effects result from the application of treatments to patients. They are commonly
negative and therefore undesirable. Side effects are one of the major causes of …

Background & Aims. The IGHV gene mutation status is a constant biological feature of tumor
cells in chronic lymphocytic leukemia (CLL). This parameter is an important predictor of the …